Author(s):
Rosaria Ika Pratiwi, Agung Endro Nugroho, Ika Puspitasari, Tri Murti Andayani
Email(s):
nugroho_ae@ugm.ac.id
DOI:
10.52711/0974-360X.2025.00098 
Address:
Rosaria Ika Pratiwi1, Agung Endro Nugroho2*, Ika Puspitasari2, Tri Murti Andayani2
1Doctoral Program in Pharmaceutical Sciences, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta, Indonesia.
2Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta, Indonesia.
*Corresponding Author
Published In:
Volume - 18,
Issue - 2,
Year - 2025
ABSTRACT:
The use of antibiotics in Community-acquired pneumonia (CAP) patients, apart from being empiric therapy, is also a definitive therapy by the results of antibiotic sensitivity tests on bacteria, so it needs to be evaluated so that the use of antibiotics becomes more rational. This study aims to determine the rationality of antibiotic use based on qualitative parameters and analyze factors that correlate with the clinical outcomes of CAP patients. This study enrolled 94 adult patients diagnosed with CAP based on inclusion and exclusion criteria. CAP patients are hospitalized in the non-VIP ward at Dr. Sardjito General Hospital, Yogyakarta, Indonesia, from September to November 2022. Qualitative evaluation of antibiotics using Gyssens categories. Assessment of antibiotic use in CAP patients based on therapy guidelines and the Carmeli Score. Factors that correlated with the clinical outcomes of CAP patients were analyzed using the bivariate and univariate tests. Empirical antibiotics assessment shows that there was the inappropriate use of antibiotics for indications (0.82%), inappropriate use of antibiotics because there are other safer antibiotics (0.82%), inappropriate use of antibiotics because there are other more effective antibiotics (8.20%), the use of antibiotics was too short (14.75%), the use of antibiotics was too long (0.82%), the use of antibiotics was not in the right dose (4.92%), the timing of antibiotics administration was inappropriate (1.64%), while the appropriate use of antibiotics was 68.03%. Definitive antibiotics assessment shows that there was the inappropriate use of antibiotics for indications (4.81%), inappropriate use of antibiotics because there were other antibiotics with a narrow spectrum (0.96%), inappropriate use of antibiotics because there are other more effective antibiotics (8.65%), the use of antibiotics was too short (20.19%), the interval of antibiotic administration was inappropriate (0.96%), the use of the antibiotics was not in the right dose (7.69%), and the timing of antibiotic administration was inappropriate (2, 89%), while the appropriate use of antibiotics was 53.85%. Factors that correlate with clinical outcomes in CAP patients are BUN levels and CAP severity. The rationality of using antibiotics for empiric therapy was 68.03% and definitive therapy was 53.85%, the most inappropriate use occurred when giving antibiotics for too short a time (20.19%). BUN levels and severity of CAP correlate with clinical outcomes in CAP.
Cite this article:
Rosaria Ika Pratiwi, Agung Endro Nugroho, Ika Puspitasari, Tri Murti Andayani. The Rationality of Antibiotic use Based on Qualitative Parameters in Community-acquired Pneumonia Therapy at General Hospital, Indonesia. Research Journal of Pharmacy and Technology.2025;18(2):661-0. doi: 10.52711/0974-360X.2025.00098
Cite(Electronic):
Rosaria Ika Pratiwi, Agung Endro Nugroho, Ika Puspitasari, Tri Murti Andayani. The Rationality of Antibiotic use Based on Qualitative Parameters in Community-acquired Pneumonia Therapy at General Hospital, Indonesia. Research Journal of Pharmacy and Technology.2025;18(2):661-0. doi: 10.52711/0974-360X.2025.00098 Available on: https://rjptonline.org/AbstractView.aspx?PID=2025-18-2-30
REFERENCES:
1. El-Sokkary RH, Ramadan RA, El-Shabrawy M, El-Korashi LA, Elhawary A, Embarak S, et al. Community acquired pneumonia among adult patients at an Egyptian university hospital: Bacterial etiology, susceptibility profile and evaluation of the response to initial empiric antibiotic therapy. Infect Drug Resist. 2018; 11: 2141–50.
2. Chen J, Li X, Wang W, Jia Y, Lin F, Xu J. The prevalence of respiratory pathogens in adults with community-acquired pneumonia in an outpatient cohort. Infect Drug Resist. 2019; 12: 2335–41.
3. Song TJ, Kim J. Effect of statins on the risk of poststroke pneumonia: National population-based cohort study. Infect Drug Resist. 2020; 13: 2689–98.
4. Azmi S, Aljunid SM, Maimaiti N, Ali AA, Muhammad Nur A, De Rosas-Valera M, et al. Assessing the burden of pneumonia using administrative data from Malaysia, Indonesia, and the Philippines. Int J Infect Dis [Internet]. 2016; 49: 87–93. Available from: http://dx.doi.org/10.1016/j.ijid.2016.05.021
5. Maniecka-Bryla I, Paciej-Golebiowska P, Dziankowska-Zaborszczyk E, Bryla M. Lost life years due to premature mortality caused by diseases of the respiratory system. Adv Clin Exp Med. 2018; 27(6): 743–8.
6. Pelton SI, Shea KM, Farkouh RA, Strutton DR, Braun S, Jacob C, et al. Rates of pneumonia among children and adults with chronic medical conditions in Germany. BMC Infect Dis. 2015; 15(1): 1–8.
7. Shoar S, Musher DM. Etiology of community-acquired pneumonia in adults: a systematic review. Pneumonia. 2020; 12(1).
8. González-Castillo J, Martín-Sánchez FJ, Llinares P, Menéndez R, Mujal A, Navas E, et al. Guidelines for the management of community-acquired pneumonia in the elderly patient. Rev Esp Quimioter [Internet]. 2014; 27(1): 69–86. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24676248
9. Nie XM, Li YS, Yang ZW, Wang H, Jin SY, Jiao Y, et al. Initial empiric antibiotic therapy for community-acquired pneumonia in Chinese hospitals. Clin Microbiol Infect. 2018; 24(6): 658.e1-658.e6.
10. Khasawneh FA, Karim A, Mahmood T, Ahmed S, Jaffri SF, Mehmood M. Safety and feasibility of antibiotic de-escalation in bacteremic pneumonia. Infect Drug Resist [Internet]. 2014; 7: 177–82. Available from: https://doi.org/10.2147/IDR.S65928
11. Michael CA, Dominey-Howes D, Labbate M. The antimicrobial resistance crisis: Causes, consequences, and management. Front Public Heal. 2014; 2(SEP): 1–8.
12. Kobayashi D, Shindo Y, Ito R, Iwaki M, Okumura J, Sakakibara T, et al. Validation of the prediction rules identifying drug-resistant pathogens in community-onset pneumonia. Infect Drug Resist. 2018; 11: 1703–13.
13. Aslam B, Wang W, Arshad MI, Khurshid M, Muzammil S, Rasool MH, et al. Antibiotic resistance: a rundown of a global crisis. Infect Drug Resist. 2018; 11: 1645–58.
14. Clarelli F, Palmer A, Singh B, Storflor M, Lauksund S, Cohen T, et al. Drug-target binding quantitatively predicts optimal antibiotic dose levels in quinolones. PLoS Comput Biol. 2020; 16(8 August): 1–27.
15. Maestro B, Sanz JM. Choline binding proteins from Streptococcus pneumoniae: A dual role as enzybiotics and targets for the design of new antimicrobials. Antibiotics. 2016; 5(2).
16. Todorova K, Maurer P, Rieger M, Becker T, Bui NK, Gray J, et al. Transfer of penicillin resistance from Streptococcus oralis to Streptococcus pneumoniae identifies murE as resistance determinant. Mol Microbiol. 2015; 97(5): 866–80.
17. Viswanathan VK. Off-label abuse of antibiotics by bacteria. Gut Microbes. 2014; 5(1): 3–4.
18. Roca I, Akova M, Baquero F, Carlet J, Cavaleri M, Coenen S, et al. The global threat of antimicrobial resistance: Science for intervention. New Microbes New Infect [Internet]. 2015; 6(January 2015): 22–9. Available from: http://dx.doi.org/10.1016/j.nmni.2015.02.007
19. Golkar Z, Bagasra O, Gene Pace D. Bacteriophage therapy: A potential solution for the antibiotic resistance crisis. J Infect Dev Ctries. 2014; 8(2): 129–36.
20. Nauclér P, Huttner A, van Werkhoven CH, Singer M, Tattevin P, Einav S, et al. Impact of time to antibiotic therapy on clinical outcome in patients with bacterial infections in the emergency department: implications for antimicrobial stewardship. Clin Microbiol Infect. 2021; 27(2): 175–81.
21. Chaudhary M, Ayub SG, Mir MA. Comparative efficacy and safety analysis of CSE-1034: An open labeled phase III study in community acquired pneumonia. J Infect Public Health. 2018; 11(5): 691–7.
22. Bernabé KJ, Langendorf C, Ford N, Ronat JB, Murphy RA. Antimicrobial resistance in West Africa: a systematic review and meta-analysis. Int J Antimicrob Agents [Internet]. 2017; 50(5): 629–39. Available from: https://doi.org/10.1016/j.ijantimicag.2017.07.002
23. Skodvin B, Wathne JS, Lindemann PC, Harthug S, Nilsen RM, Charani E, et al. Use of microbiology tests in the era of increasing AMR rates- a multicentre hospital cohort study. Antimicrob Resist Infect Control. 2019; 8(1): 1–8.
24. Peng Z, Hayen A, Kirk MD, Pearson S, Cheng AC, Liu B. Microbiology testing associated with antibiotic dispensing in older community-dwelling adults. BMC Infect Dis. 2020; 20(1): 1–9.
25. Schoffelen T, Schouten J, Hoogerwerf J, Martín Quirós A, May L, Ten Oever J, et al. Quality indicators for appropriate antimicrobial therapy in the emergency department: a pragmatic Delphi procedure. Clin Microbiol Infect. 2021; 27(2): 210–4.
26. Yulia R, Mariza JW, Soedarsono, Herawati F. Bacterial Profile and Antibiotic Use in Pneumonia Patients at Dr. Soetomo General Hospital. Curr Respir Med Rev. 2020; 16(1): 21–7.
27. Magill SS, O’Leary E, Ray SM, Kainer MA, Evans C, Bamberg WM, et al. Assessment of the Appropriateness of Antimicrobial Use in US Hospitals. JAMA Netw Open. 2021; 4(3): 1–16.
28. Loong LS, Lai PSM, Jamaluddin NAH, Naina-Mohamed I, Periyasamy P, Lau CL, et al. Comparing the appropriateness of antimicrobial prescribing among medical patients in two tertiary hospitals in Malaysia. J Infect Dev Ctries. 2022; 16(12): 1877–86.
29. Ewig S, Seifert K, Kleinfeld T, Göke N, Schäfer H. Management of patients with community-acquired pneumonia in a primary care hospital: A critical evaluation. Respir Med. 2000; 94(6): 556–63.
30. Săndulescu O, Bleotu C, Matei L, Streinu-Cercel A, Oprea M, Drăgulescu EC, et al. Comparative evaluation of aggressiveness traits in staphylococcal strains from severe infections versus nasopharyngeal carriage. Microb Pathog. 2017; 102: 45–53.
31. Lee JH, Kim HJ, Kim YH. Is β-lactam plus macrolide more effective than β-lactam plus fluoroquinolone among patients with severe community-acquired pneumonia?: A systemic review and meta-analysis. J Korean Med Sci. 2017; 32(1): 77–84.
32. Salunkhe V. Beta-lactam plus Macrolide vs Fluoroquinolone for Empiric Therapy of Hospitalized Patients with CAP: Results from the University of Louisville Pneumonia Study. J Respir Infect. 2019; 3(1): 1–9.
33. Sotgiu G, Centis R, D’Ambrosio L, Battista Migliori G. Tuberculosis treatment and drug regimens. Cold Spring Harb Perspect Med. 2015; 5(5).
34. Pinzone MR, Cacopardo B, Abbo L, Nunnari G. Duration of antimicrobial therapy in community acquired pneumonia: Less is more. Sci World J. 2014; 2014.
35. Nie W, Li B, Xiu Q. β-Lactam/macrolide dual therapy versus β-lactam monotherapy for the treatment of community-acquired pneumonia in adults: A systematic review and meta-analysis. J Antimicrob Chemother. 2014; 69(6): 1441–6.
36. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and treatment of adults with community-acquired pneumonia. Am J Respir Crit Care Med. 2019; 200(7): E45–67.
37. Castanheira M, Mills JC, Farrell DJ, Jones RN. Mutation-Driven β-Lactam resistance mechanisms among contemporary ceftazidime-nonsusceptible pseudomonas aeruginosa isolates from U.S. hospitals. Antimicrob Agents Chemother. 2014; 58(11): 6844–50.
38. Cheng WL, Hsueh PR, Lee CC, Li CW, Li MJ, Chang CM, et al. Bacteremic pneumonia caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: Appropriateness of empirical treatment matters. J Microbiol Immunol Infect [Internet]. 2016; 49(2): 208–15. Available from: http://dx.doi.org/10.1016/j.jmii.2014.05.003
39. Yu Z jian, Chen Z, Cheng H, Zheng J xin, Pan W guang, Yang W zhi, et al. Recurrent linezolid-resistant enterococcus faecalis infection in a patient with pneumonia. Int J Infect Dis [Internet]. 2015; 30: e49–51. Available from: http://dx.doi.org/10.1016/j.ijid.2014.06.017
40. Davin-Regli A, Pagès JM. Enterobacter aerogenes and Enterobacter cloacae; Versatile bacterial pathogens confronting antibiotic treatment. Front Microbiol. 2015; 6(MAY):1–10.
41. Bryce AN, Doocey R, Handy R. Staphylococcus haemolyticus meningitis and bacteremia in an allogenic stem cell transplant patient. IDCases [Internet]. 2021; 26(2021): e01259. Available from: https://doi.org/10.1016/j.idcr.2021.e01259
42. König C, Braune S, Roberts JA, Nierhaus A, Steinmetz OM, Baehr M, et al. Population pharmacokinetics and dosing simulations of ceftazidime in critically ill patients receiving sustained low-efficiency dialysis. J Antimicrob Chemother. 2017; 72(5): 1433–40.
43. Ige OM, Okesola AO. Comparative Efficacy and Safety of Cefixime and Ciprofloxacin in the Management of Adults With Community-Acquired Pneumonia in Ibadan, Nigeria. Ann Ibadan Postgrad Med [Internet]. 2015; 13(2): 72–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27162517%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC4853878
44. Dreshaj S, Doda-Ejupi T, Tolaj IQ, Mustafa A, Kabashi S, Shala N, et al. Clinical role of Cefixime in community-acquired infections. Prilozi. 2011; 32(2): 143–55.
45. MacGowan AP, Darley ESR, Jacobson SK, Smith D, Urch J. Antibiotic Guidelines 2020. North Bristol NHS Trust. 2020. 1–55 p.
46. Klement E. Guidelines on post-exposure prophylaxis for HIV and the use of co-trimoxazole prophylaxis for HIV-related infections among adults, adolescents and children: recommendations for a public health approach. World Health Organization; 2014. 1–43 p.
47. Chou CC, Shen CF, Chen SJ, Chen HM, Wang YC, Chang WS, et al. Recommendations and guidelines for the treatment of pneumonia in Taiwan. J Microbiol Immunol Infect. 2019; 52(1): 172–99.
48. Kohno S, Tateda K, Mikamo H, Kadota J ichi, Niki Y, Itamura R. Efficacy and safety of intravenous sulbactam/ampicillin 3 g 4 times daily in Japanese adults with moderate to severe community-acquired pneumonia: A multicenter, open-label, uncontrolled study. J Infect Chemother [Internet]. 2015; 21(3): 182–8. Available from: http://dx.doi.org/10.1016/j.jiac.2014.11.006
49. Munar MY., Singh H. Chronic Kidney Disease. Am Fam Physician. 2007; 75(10): 1487–96.
50. Barlam TF, Cosgrove SE, Abbo LM, Macdougall C, Schuetz AN, Septimus EJ, et al. Implementing an antibiotic stewardship program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis. 2016; 62(10): e51–77.
51. Wongsurakiat P, Chitwarakorn N. Severe community-acquired pneumonia in general medical wards: Outcomes and impact of initial antibiotic selection. BMC Pulm Med. 2019; 19(1): 1–10.
52. Postma DF, van Werkhoven CH, van Elden LJR, Thijsen SFT, Hoepelman AIM, Kluytmans JAJW, et al. Antibiotic Treatment Strategies for Community-Acquired Pneumonia in Adults. N Engl J Med. 2015; 372(14): 1312–23.
53. Prakoso I, Iryanto AP, Rahayu T, Rahma A, Rizqi MNAA, Kharisma VD, et al. Multi-epitopes Vaccine Design against Klebsiella pneumoniae based on Outer Membrane Protein using Immunoinformatics Approaches. Res J Pharm Technol. 2024; 17(1): 11–8.
54. Abbas HA, Kadry AA, Shaker GH, Goda RM. Resistance of Escherichia coli and Klebsiella pneumoniae isolated from different Sources to β-lactam Antibiotics. Res J Pharm Technol. 2017; 10(2): 589–91.
55. Hishmath M, P ZA, P SF, K V, Grinton Josvi Veigas R. Prescribing Pattern of Antimicrobials for Respiratory Tract Infections among Paediatric population in a Multi- Speciality Teaching Hospital. Res J Pharm Technol. 2023; 16(12): 5972-5977.
56. Nanda A, S D, B.K N. Antibiotic Resistance Pattern Exhibited by Esbl (Extended Spectrum β-Lactamases) in Multidrug Resistant Strains, Escherichia coli. Res J Pharm Technol. 2017; 10(11): 3705–8.
57. Antibiotic Resistance-Reasons and the Most Common Resistant Pathogens – A Review. Res J Pharm Technol. 2017; 10(6): 1886–90.
58. Rizki AT, Eli H, Riyadi A. A narrative review evaluation of resistance antibiotics used in pneumonia. Res J Pharm Technol. 2022; 15(9): 4261–9.
59. Divya MJ, Aanandhi M Vijey. An Overview on Antibiotic use and resistance. Res J Pharm Technol. 2017; 10(8): 2793–6.
60. Saleh A-FLA, Rafiuddin N, SR K. Determination of antibiotic resistant profiles for bacteria isolated from clinical samples in Aurangabad, India. Res J Pharm Technol. 2020; 13(8): 3813–6.
61. M. SM, A. SR, Abdel LHK, A. AH, Momen A. Antimicrobial Susceptibility and Resistance Profile of Pseudomonas aeruginosa Isolates from Patients at an Egyptian Hospital. Res J Pharm Technol. 2018; 11(8): 3268–72.
62. Mary TW, M. S, N. V, Sambath KR. A Review on the Irrational Antibiotics usage in Pediatrics for Respiratory Tract Infections. Res J Pharm Technol. 2019; 12(10): 5126–30.
63. Agarwa M, Joshi M, Gupta M, Bharti N, Chakrabort A, Sonigra M. Role of blood urea nitrogen and serum albumin ratio in predicting severity of community acquired pneumonia ( CAP ) om m er ci us e on on om m er al. Monaldi Arch Chest Dis. 2022; 92(2091): 1–5.
64. R. S J, B B, K G. The prognostic implication of serum albumin and BUN/Albumin ratio in assessing severity and mortality in community acquired pneumonia (CAP). Int J Clin Biochem Res. 2019; 6(1): 79–81.
65. Morley D, Torres A, Cillóniz C, Martin-Loeches I. Predictors of treatment failure and clinical stability in patients with community acquired pneumonia. Ann Transl Med. 2017; 5(22): 1–11.